Compare Stocks → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CLLSNASDAQ:OYSTNASDAQ:PRTONASDAQ:RCELNASDAQ:VCEL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$2.67+3.9%$2.74$0.96▼$3.77$142.85M3.1335,382 shs7,361 shsOYSTOyster Point Pharma$11.17$11.15$3.46▼$19.00$299.85M1.31212,171 shs330 shsPRTOProteon Therapeutics$4.00-3.6%$19.37$0.22▼$3.94$88.72M0.61.11 million shs68,384 shsRCELAVITA Medical$16.50+3.2%$16.78$9.16▼$21.70$411.05M1.39190,719 shs108,495 shsVCELVericel$52.33+5.6%$45.47$28.02▼$52.43$2.40B1.69524,472 shs576,564 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis+6.80%+8.98%-1.84%-21.24%+31.20%OYSTOyster Point Pharma0.00%0.00%0.00%0.00%0.00%PRTOProteon Therapeutics+0.25%0.00%-4.99%+112.77%+20.85%RCELAVITA Medical+3.19%+2.17%-9.84%+15.63%+21.95%VCELVericel+5.59%+14.38%+8.84%+45.28%+85.83%Warning: this could blow your mind (Ad)Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLLSCellectis2.9092 of 5 stars3.53.00.00.03.12.50.6OYSTOyster Point PharmaN/AN/AN/AN/AN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARCELAVITA Medical1.8134 of 5 stars3.53.00.00.02.70.00.6VCELVericel0.6543 of 5 stars1.52.00.00.02.00.81.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLLSCellectis3.00Buy$11.00311.99% UpsideOYSTOyster Point PharmaN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/ARCELAVITA Medical3.00Buy$27.8068.48% UpsideVCELVericel3.00Buy$46.40-11.33% DownsideCurrent Analyst RatingsLatest CLLS, OYST, PRTO, RCEL, and VCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2024VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.003/1/2024VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$51.00 ➝ $54.003/1/2024VCELVericelHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$46.00 ➝ $53.002/23/2024RCELAVITA MedicalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$19.00 ➝ $21.002/23/2024RCELAVITA MedicalCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $25.001/25/2024VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$39.00 ➝ $51.001/19/2024RCELAVITA MedicalCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$20.00 ➝ $22.001/16/2024VCELVericelHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$44.50 ➝ $46.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLLSCellectis$25.73M5.77N/AN/A$2.76 per share0.97OYSTOyster Point Pharma$24.54M12.22N/AN/A$3.80 per share2.94PRTOProteon TherapeuticsN/AN/AN/AN/A($0.06) per shareN/ARCELAVITA Medical$50.14M8.46N/AN/A$1.92 per share8.59VCELVericel$197.52M12.82$0.02 per share2,812.40$4.73 per share11.06Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLLSCellectis-$106.14M-$1.67N/A∞N/A-346.65%-73.03%-32.22%4/3/2024 (Estimated)OYSTOyster Point Pharma-$100.66M-$6.65N/AN/AN/A-901.99%-490.33%-108.29%N/APRTOProteon Therapeutics-$20.73M-$1.15N/AN/AN/AN/AN/A-118.68%N/ARCELAVITA Medical-$35.38M-$1.40N/AN/AN/A-70.56%-54.80%-38.08%5/9/2024 (Estimated)VCELVericel-$3.18M-$0.09N/A111.34N/A-1.61%-1.55%-1.02%5/8/2024 (Estimated)Latest CLLS, OYST, PRTO, RCEL, and VCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/29/2024Q4 2023VCELVericel$0.18$0.26+$0.08$0.26$64.28 million$65.00 million 2/22/2024Q4 2023RCELAVITA Medical-$0.34-$0.28+$0.06-$0.28$14.10 million$14.20 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLLSCellectisN/AN/AN/AN/AN/AOYSTOyster Point PharmaN/AN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/AN/ARCELAVITA MedicalN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLLSCellectis0.572.202.20OYSTOyster Point Pharma8.493.353.11PRTOProteon TherapeuticsN/A5.985.98RCELAVITA Medical0.817.887.46VCELVericelN/A4.494.21OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLLSCellectis63.90%OYSTOyster Point Pharma96.70%PRTOProteon Therapeutics23.03%RCELAVITA Medical27.66%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipCLLSCellectis16.41%OYSTOyster Point Pharma17.90%PRTOProteon Therapeutics45.70%RCELAVITA Medical1.96%VCELVericel5.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCLLSCellectis23155.58 million46.46 millionOptionableOYSTOyster Point Pharma30326.84 million22.04 millionNot OptionablePRTOProteon Therapeutics1722.18 millionN/ANot OptionableRCELAVITA Medical20725.71 million25.20 millionOptionableVCELVericel31448.38 million45.86 millionOptionableCLLS, OYST, PRTO, RCEL, and VCEL HeadlinesSourceHeadlineVericel (NASDAQ:VCEL) Sets New 1-Year High at $51.40marketbeat.com - March 27 at 11:23 AMVericel's (VCEL) "Buy" Rating Reaffirmed at Truist Financialamericanbankingnews.com - March 27 at 3:32 AMAnalyst Scoreboard: 5 Ratings For Vericelmarkets.businessinsider.com - March 27 at 1:54 AMTruist Financial Reaffirms "Buy" Rating for Vericel (NASDAQ:VCEL)marketbeat.com - March 26 at 9:35 AMVericel (NASDAQ:VCEL) and Twist Bioscience (NASDAQ:TWST) Head-To-Head Contrastamericanbankingnews.com - March 21 at 5:22 AMVericel Co. (NASDAQ:VCEL) Shares Sold by Public Sector Pension Investment Boardmarketbeat.com - March 20 at 4:17 AMDominick Colangelo Sells 17,500 Shares of Vericel Co. (NASDAQ:VCEL) Stockinsidertrades.com - March 17 at 5:42 AMWalleye Capital LLC Acquires New Holdings in Vericel Co. (NASDAQ:VCEL)marketbeat.com - March 17 at 4:20 AMVericel Co. (NASDAQ:VCEL) CEO Sells $781,725.00 in Stockmarketbeat.com - March 15 at 4:46 PMShort Interest in Vericel Co. (NASDAQ:VCEL) Increases By 18.8%marketbeat.com - March 15 at 3:33 PMVericel Co. (NASDAQ:VCEL) COO Sells $352,046.54 in Stockinsidertrades.com - March 14 at 9:39 AMVericel Co. (NASDAQ:VCEL) SVP Sells $367,852.95 in Stockinsidertrades.com - March 12 at 4:46 AMEnvestnet Asset Management Inc. Raises Stock Position in Vericel Co. (NASDAQ:VCEL)marketbeat.com - March 9 at 4:13 AMBaker Avenue Asset Management LP Takes $1.30 Million Position in Vericel Co. (NASDAQ:VCEL)marketbeat.com - March 8 at 8:31 AMInvesco Ltd. Cuts Stake in Vericel Co. (NASDAQ:VCEL)marketbeat.com - March 6 at 4:59 AMVericel Co. (NASDAQ:VCEL) Position Increased by Fmr LLCmarketbeat.com - March 5 at 6:27 AMVericel Co. (NASDAQ:VCEL) is Kent Lake Capital LLC's 7th Largest Positionmarketbeat.com - March 4 at 4:29 PMVCEL Oct 2024 50.000 callca.finance.yahoo.com - March 3 at 7:05 PMUS$52.07 - That's What Analysts Think Vericel Corporation (NASDAQ:VCEL) Is Worth After These Resultsfinance.yahoo.com - March 3 at 9:03 AMVericel Corporation (VCEL) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 2 at 7:12 PMVericel Full Year 2023 Earnings: EPS Beats Expectationsfinance.yahoo.com - March 2 at 8:15 AMVericel (NASDAQ:VCEL) Announces Earnings Results, Beats Estimates By $0.08 EPSmarketbeat.com - March 1 at 2:38 PMBuy Rating Affirmed for Vericel on Strong Financials and Growth Prospectsmarkets.businessinsider.com - March 1 at 12:06 PMA Closer Look at 4 Analyst Recommendations For Vericelmarkets.businessinsider.com - March 1 at 12:06 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCellectisNASDAQ:CLLSCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Oyster Point PharmaNASDAQ:OYSTOyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.Proteon TherapeuticsNASDAQ:PRTOProteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.AVITA MedicalNASDAQ:RCELAVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.VericelNASDAQ:VCELVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.